By: Clare Logan

CLN6 Gene Mutation and Epilepsy

What is the CLN6 Gene?

The CLN6 gene provides instructions for making a protein that helps cells manage and recycle waste. This process happens inside small structures in the cell called lysosomes, which act like the cell’s recycling system. The CLN6 protein helps make sure certain enzymes reach the lysosomes so they can break down materials the cell no longer needs.

When there is a change, or variant, in the CLN6 gene, this recycling process does not work correctly. As a result, waste materials build up inside cells, especially in brain cells, which are particularly sensitive to this type of damage. Over time, this buildup leads to progressive injury and loss of nerve cells in the brain. CLN6-related disease is part of a group of rare conditions called neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease. It is inherited in an autosomal recessive pattern, meaning a child must inherit one non-working copy of the gene from each parent to be affected.

CLN6-Related Epilepsy

Epilepsy is a common and often early feature of CLN6-related disease. Seizures usually begin in childhood, most often between early childhood and the school-age years, although the exact timing can vary. For many children, seizures appear alongside developmental changes, including slowing of development or loss of previously learned skills.

Seizure types can vary and may include generalized seizures, focal seizures, and sudden muscle jerks known as myoclonic seizures. Some children may also have seizures that are difficult to control with medication. Over time, seizure patterns can change as the disease progresses. CLN6-related disease affects more than just seizures. Many individuals also develop difficulties with movement and coordination, including trouble with balance, walking, and speech. Vision loss is also common in childhood-onset forms of the condition and may worsen over time. As the disease progresses, children may experience increasing challenges with thinking, communication, and physical abilities. The rate of progression and severity can differ from person to person, even among individuals with the same gene change.

Research and Treatment

There is currently no cure for CLN6-related disease. Treatment focuses on managing symptoms and supporting quality of life. Anti-seizure medications are commonly used to help reduce seizures, although they may not fully control them in all individuals. Supportive care is an important part of treatment and may include physical therapy, occupational therapy, speech therapy, vision support, and nutritional support. These services are aimed at helping children maintain function and comfort for as long as possible.

Researchers are actively studying CLN6-related disease to better understand how it develops and to explore possible treatments that may slow or change the course of the condition. Areas of research include gene-based therapies and approaches that target the underlying cell changes caused by the disease. Families affected by CLN6-related disease are often supported by a team of specialists, which may include neurologists, genetic counselors, therapists, and other medical providers. This team-based approach helps address the wide range of medical and developmental needs that can occur over time.

Resources

“Ceroid lipofuscinosis, neuronal, 6A.” National Organization for Rare Disorders (NORD). https://rarediseases.org

Delgado-Escueta AV. Epilepsy Genomics: Disease-Causing Sequence Variants. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper’s Basic Mechanisms of the Epilepsies. 5th ed. New York: Oxford University Press; 2024. Chapter 5. PMID: 39637213.

Ilyas M, Tariq F, Ishaq R, Habiba U, Bibi F, Khan SN, Ali Y, Haider S, Efthymiou S, Abdullah U, Raja GK, Shaiq PA. Whole exome sequencing identifies variable expressivity of CLN6 variants in Progressive myoclonic epilepsy affected families. Epilepsy Res. 2024 Mar;201:107283. doi: 10.1016/j.eplepsyres.2023.107283. Epub 2023 Dec 17. PMID: 38382230. 

Malik K, Santucci K, Sremba L, et al. Neuronal Ceroid Lipofuscinoses Overview. 2001 Oct 10 [Updated 2025 May 29]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1428/ 

Mole SE. The Neuronal Ceroid Lipofuscinoses. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper’s Basic Mechanisms of the Epilepsies. 5th ed. New York: Oxford University Press; 2024. Chapter 50. PMID: 39637217.

“Types of Batten Disease” Batten Disease Support and Research Association (BDSRA). https://bdsrafoundation.org/